Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJDementia
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Leukemia

DARIC33 CAR T-cells in AML 2:38
DARIC33 CAR T-cells in AML
Jacob Appelbaum • 12 May 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Identifying early predictors of neurotoxicity following CAR-T infusion 2:55
Identifying early predictors of neurotoxicity following CAR-T infusion
Jaap Boelens • 26 May 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
DARIC33: CAR T with an on/off switch 1:40
DARIC33: CAR T with an on/off switch
Jacob Appelbaum • 12 May 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS 2:29
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS
David Gilham • 22 Feb 2021
CAR T-cells in adult ALL 4:13
CAR T-cells in adult ALL
Arnon Nagler • 1 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:30
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
Infection prevention in patients receiving CAR T-cells 3:19
Infection prevention in patients receiving CAR T-cells
Joshua Hill • 10 Feb 2021
CAR-T in myeloma: key players in the therapeutic landscape 4:32
CAR-T in myeloma: key players in the therapeutic landscape
Mohamad Mohty • 26 Jan 2021
  • Previous
  • 1
  • 2
  • 3
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy